ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,86
-0,92%
Bitcoin
62 024,30
4,91%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) Actualités

BPMC Blueprint Medicines Corporation

107,195
0,195 (0,18%)
Dernière mise à jour : 21:52:11
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Blueprint Medicines Corporation BPMC NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,195 0,18% 107,195 21:52:11
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
109,82 106,07 110,93 107,00
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202413:00PRNUSBlueprint Medicines Reports Strong First Quarter 2024..
18/4/202414:00PRNUSBlueprint Medicines to Report First Quarter 2024 Financial..
11/4/202414:00PRNUSBlueprint Medicines to Host Webcast and Conference Call..
04/4/202422:01PRNUSBlueprint Medicines Announces Inducement Grants Under Nasdaq..
11/3/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:01PRNUSBlueprint Medicines Announces Inducement Grants Under Nasdaq..
06/3/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:19EDGAR2Form 144 - Report of proposed sale of securities
01/3/202421:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:03EDGAR2Form 144 - Report of proposed sale of securities
23/2/202414:00PRNUSBlueprint Medicines Highlights AYVAKIT® (avapritinib)..
22/2/202414:20EDGAR2Form 8-K - Current report
16/2/202422:40EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202423:26EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202413:05EDGAR2Form 8-K - Current report
15/2/202413:00PRNUSBlueprint Medicines Reports Fourth Quarter and Full Year..
15/2/202400:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:01PRNUSBlueprint Medicines Announces Inducement Grants Under Nasdaq..
01/2/202414:00PRNUSBlueprint Medicines to Report Fourth Quarter and Full Year..
30/1/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202422:13EDGAR2Form 144 - Report of proposed sale of securities
08/1/202414:03EDGAR2Form 8-K - Current report
08/1/202414:00PRNUSBlueprint Medicines Highlights 2024 Corporate Strategy and..
05/1/202422:01PRNUSBlueprint Medicines Announces Inducement Grants Under Nasdaq..
26/12/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:09EDGAR2Form 144 - Report of proposed sale of securities
19/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202314:00PRNUSBlueprint Medicines to Present at 42nd Annual J.P. Morgan..
15/12/202322:23EDGAR2Form 144 - Report of proposed sale of securities
13/12/202321:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202314:05PRNUSBlueprint Medicines' AYVAKYT® (avapritinib) Receives..
11/12/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202318:30PRNUSBlueprint Medicines' Leadership in Driving Continued..
08/12/202300:09EDGAR2Form 144 - Report of proposed sale of securities

Dernières Valeurs Consultées

NASDAQ
BPMC
Blueprint Medicines
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés